Oncotelic Therapeutics, Inc. (OTLC) Stock

About Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.

Oncotelic Therapeutics, Inc. is headquartered in US.

Oncotelic Therapeutics, Inc. (OTLC) stock trades at $0.04 with a market capitalization of $17.74M. The stock is valued at a price-to-earnings (P/E) ratio of 0.07, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.02 and $0.11, and currently trades 63.6% below its 52-week high.

On profitability, Oncotelic Therapeutics, Inc. generates a return on equity (ROE) of 0.00%, return on capital employed of 0.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.oncotelic.com